Peer-Reviewed Uncontrolled Trials Valid For Drug Promotions, WLF Says
Uncontrolled studies published in peer-reviewed journals should be acceptable as promotional information if disseminated with an FDA disclaimer, the Washington Legal Foundation said during FDA's public hearing on direct-to-consumer advertising Nov. 1-2
You may also be interested in...
Responding to warning and untitled letters from FDA's Division of Drug Marketing, Advertising & Communications could help to shield firms in the event of product liability suits, according to former FDA Chief Counsel Daniel Troy
An upcoming FDA draft guidance on fair balance in promotional materials could benefit manufacturers following a spate of warning letters from the agency's ad division citing the prominence of risk information
Direct-to-consumer advertising does not endanger the public health because access to prescription drugs is controlled by physicians, not the public, the Washington Legal Foundation's new advertising regulation watchdog group suggests